{"filings":[{"id":2226356,"accession_number":"0001193125-26-347911","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-08-13T11:42:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 net loss $25.3M; $50M private placement extends cash runway into Q2 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.3M ($0.40/share) vs $18.4M ($0.30) in Q2 2025; R&D $16.1M, G&A $9.9M.","Completed July 2, 2026 private placement: ~$50M upfront gross, up to $64M more if warrants exercised.","Cash, equivalents, restricted cash, and short-term investments $34.5M at June 30, 2026; runway into Q2 2027.","MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC expected Fall 2026; pembrolizumab combo update Q4 2026.","Interim CEO Tom Civik cites financing and clinical execution; shares outstanding 83.4M as of Aug 12, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1415557,"accession_number":"0001193125-26-294613","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-07-02T20:20:52+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology raises $50M upfront in private placement; warrants could add $64M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from 19.6M shares at $2.551/share; warrants at $3.289 for additional ~$64M if exercised.","Financing led by BVF Partners with GordonMD, RTW Investments, Coastlands Capital; expected close July 2, 2026.","Proceeds extend cash runway into Q2 2027; support MICVO Phase 1 monotherapy and Phase 1/2 combination studies.","Updated Phase 1 monotherapy data for 2L+ R/M HNSCC expected Fall 2026; Phase 1/2 combo data in Q4 2026.","Warrants exercisable upon earlier of public disclosure of MICVO Phase 1 data or Oct 1, 2026; expire July 2, 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1057157,"accession_number":"0001193125-26-271137","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-06-15T20:22:53+00:00","items":["5.07"],"status":"ready","headline":"Pyxis Oncology shareholders elect three Class II directors, ratify E&Y as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Quorum of 47,302,035 of 62,855,464 shares present at June 15 annual meeting.","Thomas Civik, Freda Lewis-Hall, Michael Metzger elected as Class II directors; Dr. Lewis-Hall had 10.1M withheld votes.","Ratification of Ernst & Young as independent auditor for FY 2026 passed with 46.2M for, 1.1M against.","Broker non-votes of 17,978,763 on director elections due to discretionary voting rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":77722,"accession_number":"0001193125-26-222818","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-05-14T11:36:49+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 2026 net loss $23.3M; MICVO data on track for mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.3M ($0.37/share) vs $21.2M ($0.35/share) YoY; R&D expenses rose to $20.0M from $17.0M.","Cash and equivalents $42.5M; expected runway into Q4 2026.","MICVO Phase 1 monotherapy update in 2L+ R/M HNSCC (dose cap patients) on track for mid-2026.","MICVO + pembrolizumab Phase 1/2 combination dose escalation data in 1L R/M HNSCC expected 2H 2026.","Appointed Nelson Azoulay as Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95393,"accession_number":"0001193125-26-193940","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K/A","filed_at":"2026-04-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pyxis Oncology enters CEO separation agreement: 18-mo salary, equity acceleration, board resignation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Separation Agreement with former CEO Lara Sullivan became binding April 29, 2026; she resigned from Board same day.","Dr. Sullivan will receive current salary for 18 months and health coverage for up to 12 months.","All unvested RSUs and stock options accelerated; option exercise period extended to December 31, 2030.","One-year post-separation non-solicitation and mutual non-disparagement covenants apply."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108455,"accession_number":"0001193125-26-118525","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-03-23T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology completes MICVO enrollment, reports FY2025 net loss of $79.6M, names Interim CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Completed target enrollment (n~40) for MICVO Phase 1 monotherapy dose expansion in 2L+ R/M HNSCC in Q1 2026.","Updated MICVO monotherapy data expected mid-2026; combination data with KEYTRUDA expected 2H26.","Appointed Thomas Civik as Interim CEO; added SVPs of Global Clinical Ops, IR/Capital Markets, and Global Program Leader.","Cash and investments $68.3M at Dec 31, 2025; expected cash runway into Q4 2026.","FY2025 net loss $79.6M ($1.28/diluted) vs $77.3M ($1.32) in 2024; revenue $13.9M from royalty sale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108454,"accession_number":"0001193125-26-041169","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology CEO Dr. Lara Sullivan steps down; board member Tom Civik appointed interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective February 2, 2026, Dr. Lara Sullivan stepped down as President, CEO, and CMO of Pyxis Oncology.","Board appointed Thomas Civik, a current director, as Interim CEO; base salary $710K, target bonus 60%.","Civik receives initial option grant (1.1% of shares) vesting monthly over 12 months, plus top-up (0.4%) upon successful transaction.","Board launched search for permanent CEO; Civik previously led Five Prime through its $1.9B acquisition by Amgen.","Lead program MICVO continues Phase 1/2 trials for head and neck squamous cell carcinoma; clinical operations unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124888,"accession_number":"0001193125-25-323704","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Pyxis Oncology MICVO Phase 1 shows 46% ORR monotherapy, 71% ORR with Keytruda in HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["MICVO monotherapy at 5.4 mg/kg: 46% confirmed ORR (6/13), 92% DCR in 2L+ R/M HNSCC; no Grade 4/5 TRAEs.","MICVO + Keytruda (3.6/4.4 mg/kg): 71% confirmed ORR (5/7), 100% DCR in 1L/2L+ HNSCC; no TRAE discontinuations.","Sold Enzeshu royalty rights for $11M one-time cash; cash runway extends into Q4 2026.","Monotherapy update expected mid-2026; combo update in 2H26; FDA alignment on pivotal study design obtained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124887,"accession_number":"0001193125-25-261689","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-11-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q3 net loss $22.0M; cash $77.7M, runway into H2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.0M ($0.35/share) for Q3 2025, vs $21.2M loss in Q3 2024.","Cash and equivalents $77.7M; expected to fund operations into H2 2026.","R&D expenses $17.8M; increase in MICVO costs offset by pause of PYX-106 program.","Preliminary Phase 1 data for micvotabart pelidotin (MICVO) in HNSCC expected in Q4 2025.","Translational data presented at ESMO and AACR-NCI-EORTC on MICVO's three mechanisms of action."],"consensus_eps_estimate":-0.3453,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":2820000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141594,"accession_number":"0000950170-25-108898","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 2025 net loss $18.4M, cash $90.4M; MICVO data milestones ahead","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $2.8M from milestone payment for suvemcitug approval in China, compared to $0 in Q2 2024.","Net loss $18.4M ($0.30 per share) vs $17.3M ($0.29) in prior year; adjusted loss $15.3M.","Cash, cash equivalents and short-term investments $90.4M; runway into H2 2026.","Preliminary MICVO monotherapy data in 2L/3L HNSCC expected H2 2025; combination with pembrolizumab data also H2 2025.","R&D expenses rose to $17.1M, driven by increased MICVO manufacturing and trial costs."],"consensus_eps_estimate":-0.3587,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":2820000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141593,"accession_number":"0000950170-25-101618","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology confirms HNSCC enrollment guidance for Phase 1 MICVO trial after ClinicalTrials.gov revision","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised ClinicalTrials.gov entry for MICVO (PYX-201) Phase 1 monotherapy trial reflects maximum patient enrollment per protocol.","Company reaffirms prior HNSCC patient enrollment estimates for Part 2 dose expansion as disclosed in May 15, 2025 10-Q.","No change to trial design or guidance; revision is administrative and consistent with industry practice."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141592,"accession_number":"0000950170-25-093456","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pyxis Oncology CFO/COO Pamela Connealy retires; Jitendra Wadhane appointed PFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pamela Connealy, CFO and COO, retired from Pyxis Oncology effective July 1, 2025; not due to any disagreement.","Jitendra Wadhane, current SVP Finance and CAO, appointed Principal Financial Officer effective same date.","Wadhane continues as Principal Accounting Officer; no additional compensation for PFO role.","Connealy eligible for severance benefits per her Amended and Restated Employment Agreement (Nov 2022)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159445,"accession_number":"0000950170-25-087907","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pyxis Oncology annual meeting elects three directors, ratifies EY auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Dr. Santhosh Palani, Darren Cline, and Dr. Rachel Humphrey as Class I directors until 2028.","Palani received 22,056,449 For, 7,314,363 Withheld; Cline: 22,028,914 For, 7,341,898 Withheld; Humphrey: 21,357,102 For, 8,013,710 Withheld.","Ratified Ernst & Young as independent auditor for FY2025: 43,733,259 For, 233,563 Against, 29,628 Abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159444,"accession_number":"0000950170-25-071992","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 net loss $21.2M ($0.35); cash $106.9M; MICVO data on track for H2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.2M ($0.35/share) vs $3.3M ($0.06) in Q1 2024; prior year included $16.1M Novartis settlement revenue.","Cash and investments $106.9M as of March 31, 2025; expected runway into second half of 2026.","R&D expenses rose to $17.0M from $13.0M, driven by increased clinical and manufacturing costs for MICVO.","On track to report Phase 1 monotherapy data for MICVO in HNSCC in H2 2025 and combination with pembrolizumab in H2 2025.","Preclinical data confirm three-pronged mechanism of MICVO (direct killing, bystander effect, immunogenic cell death)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177839,"accession_number":"0000950170-25-043491","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pyxis Oncology posts updated investor presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation dated March 24, 2025, posted on company IR website.","Presentation slide deck title references 'Building a Differentiated ADC Company'.","No financial results, pipeline data, or strategic updates provided in the filing.","Filing does not include any earnings, guidance, or material business developments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177838,"accession_number":"0000950170-25-040767","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.","MICVO (formerly PYX-201) achieved 50% confirmed ORR by RECIST 1.1 in R/M HNSCC Phase 1; Fast Track designation received.","Initiated MICVO monotherapy expansion cohorts and a Phase 1/2 combo trial with Merck's KEYTRUDA; data expected 2H25/1H26.","Workforce reduced ~20% primarily in G&A and preclinical; CMO Ken Kobayashi steps down; CEO Lara Sullivan to also serve as CMO.","Suspended PYX-106 development; recorded $21M non-cash impairment on PYX-107 IPR&D intangible."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177837,"accession_number":"0000950170-25-027330","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology receives FDA Fast Track for PYX-201 in head and neck cancer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA granted Fast Track Designation to PYX-201 for recurrent/metastatic HNSCC after prior chemo and anti-PD-(L)1.","PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin in the tumor extracellular matrix.","CEO Lara Sullivan called the designation a significant milestone and said trial recruitment is ongoing.","Fast Track aims to speed development and review for serious conditions with unmet medical need."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177836,"accession_number":"0000950170-25-012846","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2025-02-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology initiates combo trial PYX-201 + Keytruda and monotherapy expansion in HNSCC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 1/2 combo trial PYX-201-102 with Keytruda (pembrolizumab) in multiple solid tumors including R/M HNSCC, HR+/HER2- BC, TNBC; first dosing on track for Q1 2025.","Part 2 monotherapy expansion cohorts of Phase 1 PYX-201-101 began enrolling for 2L/3L R/M HNSCC patients who received prior platinum and PD-1 or EGFR and PD-1 inhibitors.","PYX-201 is a first-in-concept ADC targeting Extradomain-B Fibronectin (EDB+FN) in tumor extracellular matrix, designed to induce immunogenic cell death.","Combo trial is part of a Clinical Trial Collaboration Agreement with Merck (MRK)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194543,"accession_number":"0000950170-24-138563","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology prioritizes PYX-201 after 50% ORR in HNSCC; suspends PYX-106","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Confirmed 50% ORR and 100% DCR in 6 heavily pretreated HNSCC patients in Phase 1 of PYX-201.","Across 6 solid tumor types (n=31), PYX-201 achieved 26% ORR with dose-dependent responses in taxane-pretreated patients.","PYX-106 program suspended; Phase 1 monotherapy enrolled 45 patients, was safe and well-tolerated.","Current cash position expected to fund PYX-201 monotherapy and combination trials into 2H 2026.","Monotherapy and pembrolizumab combination trials for PYX-201 expected to start dosing in early 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194542,"accession_number":"0000950170-24-129238","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"PYX-201 achieves 50% ORR in HNSCC; Merck collaboration for KEYTRUDA combo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["PYX-201 achieved 50% confirmed ORR by RECIST 1.1 (1 CR, 2 PR) and 100% DCR in 6 heavily pretreated HNSCC patients.","Overall 26% ORR across six solid tumor types (n=31) with dose-dependent responses; ovarian, NSCLC, breast, sarcoma also showed shrinkage.","Entered Clinical Trial Collaboration with Merck to evaluate PYX-201 + KEYTRUDA in HNSCC, HR+/HER2- breast, TNBC, sarcoma; dosing starts Q1 2025.","PYX-201 generally well-tolerated; low incidence of Grade 3/4 TRAEs; favorable PK profile with increased stability.","Multiple Phase 1 expansion studies and combo studies to begin Q1 2025 with data readouts expected throughout 2025 and 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194541,"accession_number":"0000950170-24-124581","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology reports Q3 2024 net loss of $21.2M; cash runway into 2H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents of $146.3M as of Sept 30, 2024; expected to fund operations into 2H 2026.","Net loss of $21.2M ($0.35/share) vs $23.0M ($0.56/share) in Q3 2023.","R&D expenses rose to $17.7M from $14.7M due to increased clinical trial costs for PYX-201 and PYX-106.","Preliminary Phase 1 data for lead ADC PYX-201 to be presented at investor event on Nov 20, 2024; 80 patients dosed.","Phase 1 data for PYX-106 (Siglec-15 antibody) expected by year-end 2024; 45 patients dosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194540,"accession_number":"0000950170-24-116698","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-10-23T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Pyxis Oncology shareholders approve 5.5M share increase in equity plan at special meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted 23,234,250 to 12,829,636 to approve amendment to 2021 Equity and Incentive Plan adding 5,500,000 shares.","Proposal to adjourn if needed passed but was unnecessary; quorum of 36,189,305 shares present.","59,422,945 shares outstanding; special meeting held virtually on October 23, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210875,"accession_number":"0000950170-24-097054","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 net loss $17.3M; cash $157.2M funds into 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $17.3M ($0.29/shr) vs $15.9M ($0.41/shr) in Q2 2023; R&D spend $13.9M.","Cash, equivalents and short-term investments $157.2M as of June 30, 2024; runway into 2H 2026.","PYX-201 Phase 1: 72 subjects dosed; preliminary data (efficacy, safety, PK) expected fall 2024.","PYX-106 Phase 1: 33 subjects dosed; preliminary data (PK/PD) expected by year-end 2024.","Outstanding shares: 58,942,243 as of August 14, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":16146000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229286,"accession_number":"0000950170-24-072467","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pyxis Oncology stockholders elect four directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Santhosh Palani elected Class I director with 28,241,400 for, 93,674 withheld.","Class III directors elected: John Flavin (21,045,395 for), Lara Sullivan (24,369,861), Jakob Dupont (28,220,452).","Ratification of Ernst & Young as FY2024 auditor passed with 42,153,375 for, 151,087 against, 31,729 abstain.","Quorum of 42,336,191 shares present from 58,876,390 outstanding as of record date April 18, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229285,"accession_number":"0001193125-24-157911","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology appoints Michael A. Metzger (CEO of Syndax) to board effective June 10, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael A. Metzger appointed to Pyxis Oncology Board as Class II director, effective June 10, 2024.","Metzger is CEO of Syndax Pharmaceuticals (Nasdaq: SNDX) and has over 25 years biopharma experience.","He will serve on Audit and Compensation Committees; received stock options for 70,683 shares vesting over three years.","Board determined Metzger qualifies as independent director under Nasdaq standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229284,"accession_number":"0000950170-24-059093","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.","Cash & investments $158.5M; runway into 2H 2026; raised ~$60.8M via ATM, private placement, and Novartis deal.","PYX-201 Phase 1: 42 patients dosed; 16 more planned; results including efficacy expected fall 2024.","PYX-106 Phase 1: 24 subjects dosed; preliminary data anticipated in 2H 2024.","Appointed Stephen Worsley as Senior Vice President, Chief Business Officer."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":16146000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247878,"accession_number":"0000950170-24-037176","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology files pro forma financials for Apexigen acquisition; combined net loss $97.8M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pro forma combined net loss for FY 2023: $97.8M (basic EPS $2.29).","Purchase price for Apexigen: $10.7M, comprising 4.3M Pyxis shares at $2.295/share.","Intangible assets acquired: $24.5M (IPR&D $21.0M, royalty rights $3.5M).","Nonrecurring transaction costs included: $1.7M in Pyxis G&A, $5.5M in Apexigen G&A.","Severance costs of $4.7M recorded: $1.6M G&A, $3.1M R&D."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247877,"accession_number":"0000950170-24-036822","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology sells royalty rights to Novartis for $8M upfront cash","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["One-time $8M payment from Novartis for rights to Beovu and another asset royalties.","All prior royalties from Apexigen and Pyxis Oncology are free from reclaim.","Non-dilutive capital to support lead ADC asset PYX-201 development.","Pyxis retains rights to three other antibodies from Apexigen licensees.","$8M payment to be recorded in Q1 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247876,"accession_number":"0000950170-24-034427","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology reports FY2023 net loss of $73.8M, advances PYX-201 and PYX-106 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $73.8M ($1.85/share) vs $120.7M ($3.65/share) in FY2022; R&D expenses fell to $49.6M from $86.1M.","Cash, equivalents, and short-term investments $120.8M as of Dec 31, 2023; post-period raised $50M PIPE and $10.8M ATM, extending runway into 2H 2026.","PYX-201 Phase 1: 37 patients dosed; cleared DLT for Cohort 6; escalating to Cohort 7 at 8 mg/kg; initial data expected fall 2024.","PYX-106 Phase 1: 21 patients dosed; Cohort 5 fully enrolled at 8 mg/kg Q2W; preliminary data expected 2H 2024.","Feb 2024 PIPE investors include Deep Track Capital, Ridgeback, Blue Owl, Laurion Capital, StemPoint Capital."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247875,"accession_number":"0000950170-24-030817","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology appoints Santhosh Palani, Ph.D., CFA to board; grant of 69,760 options","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Santhosh Palani appointed to Pyxis Oncology board effective March 12, 2024.","Dr. Palani brings strategic and investment experience from PFM Health Sciences, NEA, and Cowen.","Received stock options for 69,760 shares at $5.70 exercise price, vesting over 3 years.","No committee assignments yet; independent director under Nasdaq standards.","Press release issued March 13, 2024 announcing the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":247874,"accession_number":"0000950170-24-021643","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology raises ~$50M in private placement of shares and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$50M from 8.85M shares at $4.78 and pre-funded warrants for 1.61M shares at $4.779.","Participants include Deep Track Capital, Ridgeback Capital, Blue Owl Healthcare, Laurion Capital, and StemPoint Capital.","Proceeds to fund development of lead ADC candidate PYX-201 for solid tumors and for working capital.","Private placement expected to close on or about Feb 29, 2024; registration statement to be filed by Mar 27, 2024.","Leerink Partners serving as lead placement agent; LifeSci Capital as co-placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265304,"accession_number":"0000950170-23-066245","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Pyxis Oncology appoints Ken Kobayashi as Chief Medical Officer effective Nov 27, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ken Kobayashi appointed CMO effective Nov 27, 2023; will lead clinical and regulatory operations.","Dr. Kobayashi has over 25 years of oncology drug development experience, including at Pfizer, Daiichi Sankyo, and AstraZeneca.","Employment terms: $500k base salary, 40% target bonus; inducement grant of options for 1.25% of outstanding shares.","Options vest over 4 years with 25% on 1st anniversary, then monthly; additional 0.25% vesting on milestones.","Severance: 9 months base salary and health coverage if terminated without cause or for good reason."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265303,"accession_number":"0000950170-23-060352","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology reports Q3 2023 net loss $23.0M; cuts headcount 40% to extend cash runway into early 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $23.0M ($0.56 per share) for Q3 2023, vs $27.7M ($0.85 per share) in Q3 2022.","Cash, restricted cash, and short-term investments total $134.4M as of Sept 30, 2023.","Announces 40% headcount reduction and pausing early-stage research to extend cash runway into early 2026.","PYX-201 Phase 1 fifth dose cohort at 3.6 mg/kg; preliminary data expected 1H 2024. PYX-106 refocused on NSCLC; data expected 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265302,"accession_number":"0000950170-23-056026","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K/A","filed_at":"2023-10-27T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Pyxis Oncology files Apexigen audited FY22 results; net loss $32M, cash $14.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Apexigen FY22 net loss of $32.1M, revenue $0; R&D expense $23.0M, G&A $9.7M.","Audited balance sheet at Dec 31, 2022: cash and short-term investments $16.8M, accumulated deficit $176.8M.","Auditors included going-concern doubt; Apexigen had suffered recurring losses and net capital deficiency.","The amendment provides pro forma combined financials as of June 30, 2023 and for FY22, giving effect to the August 23, 2023 acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282524,"accession_number":"0000950170-23-044036","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["2.01","5.02","7.01","9.01"],"status":"ready","headline":"Pyxis Oncology completes all-stock acquisition of Apexigen for ~$10.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pyxis issued ~4.3M shares (exchange ratio 0.1725) so Apexigen holders own ~10% of combined co.","Acquisition adds clinically validated APXiMAB antibody-discovery platform and Phase 2 CD40 agonist sotigalimab (now PYX-107).","Combined co. positions for next-gen ADC creation; cash runway extended into 1H 2025.","Jakob Dupont, former Apexigen director, appointed to Pyxis board as independent Class III director.","Development strategy and timelines for PYX-107 to be shared in 4Q23."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282523,"accession_number":"0000950170-23-041601","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 net loss $15.9M; cash $144.1M; Apexigen deal on track for August close","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $15.9M ($0.41/share) vs $25.6M ($0.79) in Q2 2022; loss narrowed on lower R&D and G&A.","Cash and short-term investments $144.1M as of June 30, 2023; expected runway into first half of 2025.","R&D expenses $11.4M (down from $17.2M YoY); G&A $6.7M (down from $8.6M YoY).","Third dose cohort initiated in Phase 1 trial of ADC PYX-201; three European sites recruiting.","Apexigen acquisition expected to close later in August 2023; sotigalimab development plan in Q4."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":282522,"accession_number":"0000950170-23-041578","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Pyxis Oncology to merge with Apexigen in stock deal; Pyxis shareholders to own 90% of combined company","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Exchange ratio: 0.1725 Pyxis shares per Apexigen share; combined ownership ~90% Pyxis, ~10% Apexigen.","Estimated purchase price ~$15.1M based on Pyxis closing price of $3.19 on June 5, 2023.","Pro forma combined net loss for FY2022: $158.9M; for Q1 2023: $25.3M.","Pro forma combined cash and marketable securities ~$161.4M as of March 31, 2023.","Apexigen options, RSUs, and warrants assumed and converted with substantially similar terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301751,"accession_number":"0000950170-23-031128","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pyxis Oncology expands board to 7, appoints Dr. Jakob Dupont as director contingent on Apexigen merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased to seven members, effective upon closing of merger with Apexigen.","Dr. Jakob Dupont appointed as Class III director, term expiring at 2024 annual meeting.","Dr. Dupont executed voting agreement to support merger proposals; no other arrangements or family ties.","Appointment contingent on merger completion; Dr. Dupont eligible for non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301750,"accession_number":"0000950170-23-027742","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Pyxis Oncology shareholders elect three directors and ratify auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Rachel Humphrey, M.D. elected as Class I director: 13,536,830 for, 3,476,861 withheld, 10,500,726 broker non-votes.","Freda Lewis-Hall, M.D. elected as Class II director: 13,597,586 for, 3,416,105 withheld, 10,500,726 broker non-votes.","Thomas Civik elected as Class II director: 13,452,770 for, 3,560,921 withheld, 10,500,726 broker non-votes.","Ratification of Ernst & Young LLP as FY2023 auditor passed: 27,404,246 for, 80,518 against, 29,653 abstain, no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301749,"accession_number":"0000950170-23-023946","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pyxis Oncology announces acquisition of Apexigen; no deal terms disclosed","summary_kind":"llm","event_type":"m_and_a","confidence":"low","bullets":["Pyxis Oncology and Apexigen held a joint investor call on May 24, 2023 to discuss the proposed business combination.","Financial terms of the acquisition were not disclosed in the filing.","The transaction is subject to customary closing conditions, including stockholder and regulatory approvals.","Pyxis plans to file a registration statement on Form S-4 in connection with the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301748,"accession_number":"0000950170-23-023753","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-05-24T23:59:59+00:00","items":["1.01","5.02","7.01","8.01","9.01"],"status":"ready","headline":"Pyxis Oncology acquires Apexigen in ~$16M all-stock deal; CMO resigns","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger valued at ~$16M enterprise value; implied $0.64 per Apexigen share; exchange ratio 0.1725 PYXS shares per APGN share.","Pyxis stockholders to own ~90% of combined company; Apexigen stockholders ~10%; deal expected to close mid-2023.","Adds klinical-stage CD40 agonist sotigalimab (Phase 2) and APXiMAB antibody platform to Pyxis' FACT ADC toolkit.","Cash runway extended into first half of 2025 per company guidance.","CMO Jay Feingold steps down effective June 15, 2023; will serve as advisor until successor is named."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":301747,"accession_number":"0000950170-23-020833","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q1 net loss $19.2M; cash $150.8M; ODD for PYX-201 in pancreatic cancer","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.2M ($0.54 per share) vs $31.4M ($0.97) in Q1 2022; R&D expenses $11.9M, G&A $9.1M.","Cash, equivalents, restricted cash and short-term investments $150.8M, no debt; runway into 1H 2025.","FDA granted Orphan Drug Designation for PYX-201 in pancreatic cancer; Phase 1 trial dosing underway.","Phase 1 trial of PYX-106 dosing expected to begin Q2 2023; preliminary data from both trials late 2023 to early 2024.","One-time $8M payment to Pfizer in Q1 for FACT platform license expansion."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321514,"accession_number":"0000950170-23-010318","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-03-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pyxis Oncology reprices executive stock options to $2.21 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved reducing exercise prices of outstanding pre-IPO options from $5.34-$8.71 to $2.21, the closing price on March 24, 2023.","CEO Lara Sullivan had 1,052,286 options repriced; CFO/COO Pamela Connealy 332,569; CMO Jay Feingold 174,774.","Repricing applies only to options granted under the 2019 Plan to current employees; all other terms unchanged.","Board cites improved retention and motivation without additional equity dilution or cash compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321513,"accession_number":"0000950170-23-009044","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-03-22T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pyxis Oncology FY2022 net loss $120.7M; CFO promoted to CFO & COO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $120.7M ($3.65/share) vs $76.0M ($8.95) in 2021; R&D spend rose to $86.1M from $51.0M.","Cash $180.7M with no debt as of Dec 31, 2022; runway into 1H 2025.","Two Phase 1 trials for PYX-201 and PYX-106 initiated; preliminary data expected late 2023 to early 2024.","CFO Pam Connealy promoted to additional role of COO effective March 22, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":321512,"accession_number":"0000950170-23-008307","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Pyxis Oncology doses first subject in Phase 1 trial of ADC PYX-201 for solid tumors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First subject dosed in open-label, dose-escalation Phase 1 trial PYX-201-101; preliminary data expected early 2024.","PYX-201 targets EDB fibronectin, overexpressed in many solid tumors; minimal expression in normal adult tissues.","Trial enrolling patients with NSCLC, HR+ breast, ovarian, thyroid, pancreatic, sarcoma, hepatocellular, kidney cancers.","PYX-201 uses FACT platform licensed from Pfizer (2021) for site-specific conjugation and improved safety profile.","Dosing milestone marks transition of Pyxis Oncology to a clinical-stage company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339619,"accession_number":"0000950170-22-025912","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2022-12-01T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA clears Pyxis Oncology INDs for PYX-201 ADC and PYX-106 immunotherapy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA cleared IND for PYX-201, an ADC targeting tumor microenvironment for breast, head/neck, lung, thyroid cancers.","FDA cleared IND for PYX-106, an immunotherapy targeting Siglec-15 for bladder, cholangiocarcinoma, colorectal, kidney cancers.","Phase 1 trials planned to start in early 2023; cash runway extended into first half 2025.","Pyxis Oncology transitions to clinical-stage company with veteran leadership team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339618,"accession_number":"0000950170-22-020699","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2022-11-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q3 net loss $27.7M, expands Pfizer ADC licensing deal","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $27.7M ($0.85 per share) for Q3 2022 vs. $14.2M ($8.96 per share) in Q3 2021.","Cash and cash equivalents (incl. restricted) $200.0M as of Sept 30, 2022; expected to fund operations into end of 2024.","Expanded worldwide licensing deal with Pfizer for exclusive rights to Pfizer’s ADC technology platform and toolkit.","First multi-target sublicensing agreement executed with a stealth ADC company under the new Pfizer arrangement.","IND filings for PYX-106 and PYX-201 on track by end of 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":339617,"accession_number":"0001193125-22-259636","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2022-10-07T23:59:59+00:00","items":["1.01","3.02"],"status":"ready","headline":"Pyxis Oncology enters amended license deal with Pfizer for ADC platform; pays $8M cash + $10M in stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Pyxis pays Pfizer $8M cash and issues ~2.23M shares ($5M) on closing, plus $5M in shares 180 days later.","Pfizer grants exclusive worldwide rights to FACT platform for ADCs targeting PYX-201 and PYX-203.","Shares are unregistered, relying on Section 4(a)(2) exemption from the Securities Act.","Post-issuance, Pyxis had ~35.1M shares outstanding as of October 6, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356976,"accession_number":"0000950170-22-017220","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2022-08-15T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Pyxis Oncology Q2 net loss $25.6M, cash $207M; stops PYX-202, prioritizes two lead programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $207M as of Aug 15, 2022; expected to fund operations through second half of 2024.","Q2 net loss $25.6M ($0.79/sh) vs $8.1M ($5.54/sh) in 2021; R&D expense $17.2M (from $3.2M).","Prioritizes PYX-201 (anti-EDB ADC) and PYX-106 (anti-Siglec-15 mAb) for IND filings in H2 2022.","Ceases development of PYX-202 (anti-DLK1 ADC) after toxicology data; pauses PYX-203 and PYX-102.","Appoints Dr. Rachel Humphrey to Board; receives option grant for 236,220 shares at $2.91."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":356975,"accession_number":"0000950170-22-016063","cik":1782223,"company_name":"Pyxis Oncology, Inc.","ticker":"PYXS","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Pyxis Oncology appoints Jitendra Wadhane as Chief Accounting Officer","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Mr. Wadhane appointed CAO and Principal Accounting Officer effective August 3, 2022.","He previously served as SVP of Finance and Corporate Controller since August 2021.","Prior roles include Head of SEC Reporting at Immunovant and Senior Manager at EY.","He is a CPA with a Bachelor's from University of Mumbai and Chartered Accountancy from ICAI.","No family relationships or arrangements with other directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":113089533.45086706,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-09T23:59:59+00:00|356975"}